Vildagliptin - new opportunities in the treatment of type 2 diabetes mellitus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the role of incretin drugs in the treatment of patients with type 2 diabetes mellitus (DM2). The mechanisms of action of dipeptidyl peptidase type 4 inhibitors (iDPP-4) are analyzed using the example of vildagliptin. The data of studies on the effectiveness of vildagliptin as monotherapy and in combination with metformin, sulfonylurea drugs, thiazolidinediones are presented. The results of observational programs to evaluate the efficacy and safety of the use of vildagliptin and a fixed combination of vildagliptin and metformin in real clinical practice are presented. Conclusion. The emergence of iDPP-4 has significantly expanded the possibilities for effective and safe treatment of type 2 diabetes. These drugs, and vildagliptin in particular, are safe, easy to use, and well tolerated by patients. And their possible effect on atherogen-esis, vascular endothelium and vascular wall allows us to hope for a cardioprotective effect.

Full Text

Restricted Access

About the authors

Maria G. Pavlova

Sechenov University

Email: pavlova_m_g@staff.sechenov.ru
Cand. Sci. (Med.), Associate Professor at the Department of Endocrinology Moscow, Russia

References

  1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск (дополненный). М., 2021.
  2. Дедов И.И, Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-112.
  3. Deacon C.F, Nauck M.A., Toft-Nielsen M., et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diab. 1995;44:1126-31. Doi: 10.2337/ diab.44.9.1126.
  4. Ahren B, Simonsson E., Larsson H., et al. Inhibition of dipeptidylpeptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diab Care. 2002;25:869-75. doi: 10.2337/diacare.25.5.869.
  5. Шестакова Е.А., Галстян Г.Р. Ингибиторы дипеп-тидилпептидазы-4: сравнительный анализ. Проблемы эндокринологии. 2012;1:61-6.
  6. Инкретины: новая веха в лечении СД 2 типа. Практическое руководство для врачей. Под ред. И.И. Дедова., М.В. Шестаковой М., 2010. 92 с.
  7. Lyu X., et al. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Sci Rep. 2017;7:44865. doi: 10.1038/srep44865.
  8. Schweizer A., Couturier A., Foley J.E., Dejager S.Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diab Med. 2007;24:955-61. doi: 10.1111/Ј.1464- 5491.2007.02191.x.
  9. Dejager S., Le Beaut A., Couturier A., Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). ADA Ann Meeting. 2006;(abstract 120-OR).
  10. Rosenstock J., et al.Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. A 24-week, double-blind, randomized trial. Diab Care 2007;30:217-23. Doi: 10.2337/ dc06-1815.
  11. Pan C., Yang W., Barona J.P, et al.Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomised trial. Diab Med. 2008;25(4):435-41 doi: 10.1111/j.1464-5491.2008.02391.x.
  12. Bosi E., Camisasca R.P, Collober C., et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diab Care. 2007;30:890-95. doi: 10.2337/dc06-1732.
  13. Garber A., et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylurea. Diab Obes Metab. 2008;10(11):1047-56. doi: 10.1111/j.1463-1326.2008.00859.x.
  14. El-Ouaghlidi A., Rehring E.R., Schweizer A., et al. The dipeptidyl peptidase IV inhibitor LAF237 does not accentuate reactive hypoglycemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects. Diab. 2003;52:A118.
  15. Ferrannini E, Fonseca V., Zinmanet B, et al. et al. 52-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diab Obes Metab. 2009;11:157-66. doi: 10.1111/j.1463-1326.2008.00994.x.
  16. Павлова М.Г, А.В. Зилов. Как избежать опасности гипогликемии - одного из важнейших осложнений терапии сахарного диабета 2-го типа? Роль ингибиторов ДПП-4. Проблемы эндокринологии. 2011;57(3):48-52.
  17. Демидова Т.Ю., Томилова Е.Н. ИДПП-4: 10 лет эффективного и безопасного управления сахарным диабетом 2 типа. Русский медицинский журнал. 2018;11(II):95-100.
  18. Fonseca V., Schweizer A., Albrecht D., et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetol. 2007;50:1148-55. doi: 10.1007/s00125-007-0633-0.
  19. Dunning B.E., Ligueros-Saylan. Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metformin-treated patients with type 2 diabetes. Presented at EASD 2006;abstract 0174.
  20. Schweizer A., Couturier A., Foley J.E., Dejager S.Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with type 2 diabetes. Diab Med. 2007;24:955-61. doi: 10.1111/j.1464- 5491.2007.02191.x.
  21. Павлова М.Г. Новые возможности терапии сахарного диабета 2 типа. Результаты пилотной наблюдательной программы по эффективности и безопасности терапии препаратом Галвус (вилдаглиптин) в Москве и регионах Российской Федерации. Фарматека. 2010;3( 197):87-90.
  22. Павлова М.Г, Зилов А.В. Ингибиторы дипеп-тидил-пептидазы-4 в рутинной клинической практике - оценка эффективности и безопасности разных режимов терапии. Лечащий врач. 2012;03
  23. Абаева М.Ш., Нажмутдинова П.К., Аметов А.С. Влияние комбинации метформина и вилда-глиптина на показатели углеводного и жирового обменов у больных сахарным диабетом 2 типа. Фарматека. 2014;5:19-25
  24. Демидов Н.А,КотешковаО.М, Балберова М.А., Анциферов М.Б. Старт терапии сахарного диабета 2 типа с фиксированной комбинацией. Метформин с вилдаглиптином или с глибенкламидом, есть ли разница? Фарматека. 2019;14:47-53 Doi: 10.18565/ pharmateca.2019.14.47-53.
  25. Сахарный диабет. Оригинальное исследование. [Diabetes Mellitus © Endocrinology Research Centre, 2020 Received: 22.06.2020. Accepted: 18.12.2020. (In Russ.)]
  26. Демидов Н.А., Анциферов М.Б., Зилов А.В. Результаты клинического исследования эффективности и безопасности фиксированной комбинации вилдаглиптин+метформин в реальной клинической практике в России (исследование мастер). Сахарный диабет. 2020;23(6):514-22 doi: 10.14341/DM1250.
  27. Matthews D.R., Paldanius P.M., Proot P., et al: VERIFY study group. Glycaemic Durability Of An Early Combination Therapy With Vildagliptin And Metformin Versus Sequential Metformin Monotherapy In Newly Diagnosed Type 2 Diabetes (Verify): A 5-Year, Multicentre, Randomised, Double-Blind Trial. Lancet. 2019;394(10208):1519-29. Doi: 10.1016/ S0140-6736(19)32131-2.
  28. Subrahmanyan N.A., Koshy R.M. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors. Curr Drug Saf. 2021;16(2):154-64. Doi: 10.2174/1 574886315999200819150544.
  29. Mannucci E., Nreu B., Montereggi C., et al. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021;31(10):2745-55 doi: 10.14341/DM1250.
  30. doi: 10.1016/j.numecd.2021.06.002.
  31. Zannad F., Stough W.G., Lipicky R.J., et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016;2:200-5. Doi: 10.1093/ ehjcvp/pvw007.
  32. Mathieu C., Kozlovsky P, Foley J.E., et al. Clinical Safety and tolerability of vildagliptin -insights from randomised trials, observational studies and post-marketing surveillance. Eur Endocrinol. 2017;13(2):68-72. Doi: 10.17925/ EE.2017.13.02.68.
  33. McInnes G., Evans M., Del Prato S., et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diab Obes Metab. 2015;17:1085-92. doi: 10.1111/dom.12548.
  34. Wicinmski M., Gorski K., Wodkiewicz E., et al. Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis.Int J Mol Sci. 2020;21(7):2275. doi: 10.3390/ijms2 1 0722 75.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies